| Literature DB >> 22904336 |
Edith R Lederman1, Whitni Davidson, Harold L Groff, Scott K Smith, Tyler Warkentien, Yu Li, Kimberly A Wilkins, Kevin L Karem, Rama S Akondy, Rafi Ahmed, Michael Frace, Wun-Ju Shieh, Sherif Zaki, Dennis E Hruby, Wendy P Painter, Kimberly L Bergman, Jeffrey I Cohen, Inger K Damon.
Abstract
Progressive vaccinia (PV) is a rare but potentially lethal complication that develops in smallpox vaccine recipients with severely impaired cellular immunity. We describe a patient with PV who required treatment with vaccinia immune globulin and who received 2 investigational agents, ST-246 and CMX001. We describe the various molecular, pharmacokinetic, and immunologic studies that provided guidance to escalate and then successfully discontinue therapy. Despite development of resistance to ST-246 during treatment, the patient had resolution of PV. This case demonstrates the need for continued development of novel anti-orthopoxvirus pharmaceuticals and the importance of both intensive and timely clinical and laboratory support in management of PV.Entities:
Mesh：
Substances：
Year: 2012 PMID： 22904336 PMCID： PMC3529603 DOI： 10.1093/infdis/jis510
Source DB: PubMed Journal: J Infect Dis ISSN： 0022-1899 Impact factor: 7.759